PTGS2 and cardiac hypertrophy: Zhang et al. showed that SB administration (1 g/kg/d) inhibited the activation of the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway in a HDAC5/HDAC6-dependent manner, contributing to reducing Ang II-induced heart hypertrophy, mean arterial pressure and inflammation (Zhang et al., 2019).